Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation

2009 ◽  
Vol 16 (3) ◽  
pp. 195-204 ◽  
Author(s):  
Valkal Bhatt ◽  
Nancy Vendrell ◽  
Karen Nau ◽  
Deborah Crumb ◽  
Vivek Roy
Keyword(s):  
Cell Transplantation ◽  
Oral Mucositis ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Standardized Protocol

Efficacy of keratinocyte growth factor in prevention of oral mucositis in children undergoing allogeneic hematopoietic cell transplantation

2020 ◽  
Vol 51 (3) ◽  
pp. 172-178
Author(s):  
Natalia Bartoszewicz ◽  
Krzysztof Czyżewski ◽  
Robert Dębski ◽  
Anna Krenska ◽  
Ewa Demidowicz ◽  
...  
Keyword(s):  
Growth Factor ◽  
Cell Transplantation ◽  
Oral Mucositis ◽  
Hematopoietic Cell Transplantation ◽  
Clinical Course ◽  
Keratinocyte Growth Factor ◽  
Supportive Therapy ◽  
Primary Objective ◽  
Hematopoietic Cell ◽  
Unrelated Donor

AbstractIntroductionOral mucositis is regarded by patients as one of the worst and debilitating complications of conditioning and hematopoietic cell transplantation (HCT). Prevention of mucositis is one of the priorities of supportive therapy during and after conditioning.ObjectivesThe primary objective of the study was the analysis of efficacy of keratinocyte growth factor (KGF, palifermin) used in prophylaxis of oral mucositis in patients undergoing allo-HCT. The secondary objectives of the study included the analysis of the influence of palifermin on clinical course of oral mucositis and early transplant outcomes, as well as analysis of the contraindications of palifermin in patients undergoing allo-HCT.Patients and methodsA total number of 253 allo-HCT performed between 2003 and 2018 in patients aged 0–19 years in a single center were analyzed. Overall, in 161 HCTs, palifermin was administered.ResultsPatients receiving KGF were transplanted earlier in the context of calendar year, and more often received ATG, mainly due to the higher rate of unrelated donor transplants. Allo-HCT patients who were administered palifermin had shorter time of mucositis (median: 9 vs. 13 days, p < 0.001), lower mucositis grade (median: 2° vs. 3°; p < 0.001), shorter period of total parenteral nutrition (median: 19 vs. 22 days; p = 0.018), and lower incidence of episodes of febrile neutropenia (median: 39.1% vs. 83.1%; p < 0.001).ConclusionsThe use of palifermin has decreased duration and severity of oral mucositis in children after allo-HCT. Palifermin is a safe and well-tolerated compound in children undergoing allo-HCT.

Severity of Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation and an Oral Laser Phototherapy Protocol: A Survey of 30 Patients

2008 ◽  
pp. 100621062336065-8 ◽  
Author(s):  
Fernanda de Paula Eduardo ◽  
Leticia Bezinelli ◽  
Ana Claudia Luiz ◽  
Luciana Correa ◽  
Cristina Vogel ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Oral Mucositis ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Laser Phototherapy

Severity of Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation and an Oral Laser Phototherapy Protocol: A Survey of 30 Patients

2009 ◽  
Vol 27 (1) ◽  
pp. 137-144 ◽  
Author(s):  
Fernanda de Paula Eduardo ◽  
Leticia Bezinelli ◽  
Ana Claudia Luiz ◽  
Luciana Correa ◽  
Cristina Vogel ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Oral Mucositis ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Laser Phototherapy

scholarly journals Impact of LEAM and CBV conditioning on gastrointestinal toxicity at early periods following hematopoietic cell transplantation: A retrospective study

JBMTCT ◽  
2021 ◽  
Vol 2 (2) ◽  
pp. p51
Author(s):  
Cristina De Paula Novaes
Keyword(s):  
Overall Survival ◽  
Digestive Tract ◽  
Cell Transplantation ◽  
Oral Mucositis ◽  
Medical Records ◽  
Hematopoietic Cell Transplantation ◽  
Gastrointestinal Toxicity ◽  
Hematopoietic Cell ◽  
Gastrointestinal Mucositis

Objectives: To compare the severity of oral mucositis and the frequency of gastrointestinal mucositis, and to observe if there is impact of these adverse effects on overall survival (OS), in patients who underwent CBV (carmustine, BCNU, and VP-16) and LEAM (lomustine, etoposide, Ara-C, and melphalan) conditioning for autologous hematopoietic cell transplantation (aHCT). Method: We collected retrospective data from medical records (n = 120) of transplantation and mucositis in the digestive tract of Hodgkin’s and non-Hodgkin’s lymphoma patients. Results: The frequency of OM grade 1 was higher in LEAM (36.76%) than in CBV (19.72%, p=0.038). There were no significant differences between the frequency of gastrointestinal mucositis in the two regimens (CBV - 52.11% and LEAM - 63.27%, p=0.305). CBV regimen exhibited lower 1-year overall survival (OS) than did LEAM (p=0.003). Oral mucositis grade ≥2 was associated with reduced OS in the CBV group (p=0.013). CBV regimen (HR=2.98, p 0.005) and oral mucositis grade ≥2 (HR=2.17, p=0.013) interfered negatively on the OS rate. Conclusion: Oral mucositis was more severe in CBV than in LEAM, decreasing the OS rate. Further studies with comprehensive follow-up and toxicity analyses must be undertaken to clarify the safety of LEAM conditioning in the digestive tract.

Sign in / Sign up

Export Citation Format

Share Document